RESEARCH TRIANGLE PARK, N.C. & TURNHOUT, BELGIUM – January 28, 2010 – Quintiles today announced a strategic alliance with Movetis NV for commercialization of its new product, Resolor (prucalopride), in the U.K. and Germany. Under the alliance, Quintiles will execute a comprehensive commercial sales effort for the product launch and provide additional services in consulting, market access, market intelligence and analytics, regulatory and post-marketing pharmacovigilance. The agreement is expected to be extended later this year to cover other selected European countries.

Movetis is a European specialty pharmaceutical company focused on the discovery, development and commercialization of proprietary and innovative drugs for the treatment of diseases in the gastrointestinal (GI) area. Movetis obtained approval for the commercialization of Resolor in the European Economic Area for the symptomatic treatment of chronic constipation for women in whom laxatives fail to provide adequate relief.

Chris Pepler, Senior Vice President of Global Business Development and Operations for Quintiles said: “This agreement is an example of how leading specialty pharma companies are building partnerships that extend beyond the traditional Commercial Sales Organization model to manage risk, increase productivity, overcome complexity and demonstrate value to stakeholders in the New Health. We are pleased that Movetis has chosen to leverage Quintiles’ suite of comprehensive services, including our product and brand solutions, to help ensure the commercial success of Resolor.”

Movetis CEO Dirk Reyn said: “We are confident that our alliance with Quintiles will help drive our goal of becoming a successful European specialty GI company. The launch of Resolor will be a key milestone as we continue to build on our expertise in bringing new GI drugs from discovery to marketing.”

About Movetis
Movetis is a European specialty GI company that is focused on improving the lives of millions of patients – both adults and children – by discovering, developing and commercializing innovative treatments targeting GI conditions with a high unmet medical need. Movetis NV was founded in Belgium in November 2006 as a spin-off of Johnson & Johnson.

In addition to Resolor, Movetis has a broad portfolio of GI products: two products are in Phase II development and Movetis has two prioritized compounds in preclinical development, all addressing important GI areas including ascites, pediatric reflux, refractory GERD (gastroesophageal reflux disease) and severe forms of irritable bowel syndrome. In addition, Movetis has rights to a large library of qualified lead compounds with potential for development in different GI indications, and access to know-how for compounds in secretory diarrhoea. The current portfolio is licensed from Janssen Pharmaceutica NV, Belgium and Ortho-McNeil Pharmaceutical Inc., two Johnson & Johnson companies. Movetis shares are listed on Euronext Brussels under the ticker MOVE.

About Quintiles
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of 23,000 engaged professionals in more than 50 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit

Forward-Looking Statements
This press release contains “forward-looking statements,” based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from expectations and projections. Risks and uncertainties include, among other things, general industry conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to product marketing, such as the unpredictability of market acceptance for new products; inconsistency of treatment results among patients; the potential for product failures; potential difficulties in manufacturing; governmental laws and regulations affecting domestic and foreign operations and the ongoing success of the collaboration. The parties expressly disclaim any intent or obligation to update these forward-looking statements except as required to do so by law.

# # #